Bridging the gap: Lessons we have learnt from the merging of psychology and psychiatry for the optimisation of treatments for emotional disorders

Behaviour Research and Therapy

Volumn 62, Issue , 2014, Pages 3-16

  Graham, Bronwyn M ^a   Callaghan, Bridget L ^a   Richardson, Rick ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anxiety; Cognitive behavioural therapy; Depression; Fear conditioning; Fear extinction; Pharmacotherapy

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TIANEPTINE;

AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; COGNITIVE THERAPY; DEPRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG EXPOSURE; EMOTIONAL DISORDER; FEAR; HUMAN; INSOMNIA; LEARNING; MOLECULAR MECHANICS; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHIATRY; PSYCHOLOGY; PSYCHOTHERAPY; REINFORCEMENT; SOCIAL PHOBIA; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANXIETY DISORDERS; DEPRESSIVE DISORDER; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; EXTINCTION, PSYCHOLOGICAL; FEAR; HUMANS; PSYCHIATRY; PSYCHOLOGY; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 84910083551     PISSN: 00057967     EISSN: 1873622X     Source Type: Journal    
DOI: 10.1016/j.brat.2014.07.012     Document Type: Article

References (123)

1. Arch J.J., Craske M.G. Implications of naturalistic use of pharmacotherapy in CBT treatment for panic disorder. Behaviour Research and Therapy 2007, 45:1435-1447.
2. Barlow D.H., Allen L.B., Choate M.L. Toward a unified treatment for emotional disorders. Behavior Therapy 2004, 35:205-230.
3. Baioui A., Pilgramm J., Kagerer S., Walter B., Vaitl D., Stark R. Neural correlates of symptom reduction after CBT in obsessive-compulsive washers-An fMRI symptom provocation study. Journal of Obsessive-compulsive and Related Disorders 2013, 2:322-330.
4. Beck A.T. Cognitive therapy for the emotional disorders 1976, International Universities Press, New York.
5. Berry A.C., Rosenfield D., Smits J.A.J. Extinction retention predicts improvement in social anxiety symptoms following exposure therapy. Depression and Anxiety 2009, 26:22-27.
6. Blechert J., Michael T., Vriends N., Margraf J., Wilhelm F.H. Fear conditioning in posttraumatic stress disorder: evidence for delayed extinction of autonomic, experiential, and behavioural responses. Behaviour Research and Therapy 2007, 45:2019-2033.
7. Bos M.G.N., Beckers T., Kindt M. The effects of noradrenergic blockade on extinction in humans. Biological Psychology 2012, 89:598-605.
8. Bouton M.E., Kenney F.A., Rosengard C. State-dependent fear extinction with two benzodiazepine tranquilizers. Behavioral Neuroscience 1990, 104:44-55.
9. Bouton M.E., Vurbic D., Woods A.M. D-Cycloserine facilitates context-specific fear extinction learning. Neurobiology of Learning and Memory 2008, 90:504-510.
10. Brunet A., Poundja J., Tremblay J., Bui E., Thomas E., Orr S., et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. Journal of Clinical Psychopharmacology 2011, 31:547-550.
11. Burghardt N.S., Sigurdsson T., Gorman J.M., McEwen B.S., LeDoux J.E. Chronic antidepressant treatment impairs the acquisition of fear extinction. Biological Psychiatry 2013, 73:1078-1086.
12. Burgos-Robles A., Vidal-Gonzalez I., Quirk G.J. Sustained conditioned responses in prelimbic prefrontal neurons are correlated with fear expression and extinction failure. The Journal of Neuroscience 2009, 29:8474-8482.
13. Burgos-Robles A., Vidal-Gonzalez I., Santini E., Quirk G.J. Consolidation of fear extinction requires NMDA receptor-dependent bursting in the ventromedial prefrontal cortex. Neuron 2007, 53:871-880.
14. Cain C.K., Blouin A.M., Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. Learning & Memory 2004, 11:179-187.
15. Chason G.S., Buhlmann U., Tolin D.F., Rao S.R., Reese H.R., Rowley T., et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d- cycloserine. Behaviour Research and Therapy 2010, 48:675-679.
16. Cisler J.M., Steele J.S., Lenow J.K., Smitherman S., Everett B., Messias E., et al. Functional reorganization of neural networks during repeated exposure to the traumatic memory in posttraumatic stress disorder: an exploratory fMRI study. Journal of Psychiatric Research 2014, 48:47-55.
17. Clark D.M. Developing new treatments: on the interplay between theories, experimental science and clinical innovation. Behaviour Research and Therapy 2004, 42:1089-1104.
18. Corcoran K.A., Quirk G.J. Activity in prelimbic cortex is necessary for the expression of learned, but not innate, fears. The Journal of Neuroscience 2007, 27:840-844.
19. Cuijpers P., van Straten A., Warmerdam L., Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depression and Anxiety 2009, 26:279-288.
20. Davidson J.R.T., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 2004, 61:1005-1013.
21. Davis M. The role of the amygdala in fear and anxiety. Annual Review of Neuroscience 1992, 15:353-375.
22. De Kleine R.A., Hendriks G.-J., Smits J.A.J., Broekman T.G., van Minnen A. Prescriptive variables for D-cycloserine augmentation of exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Research 2014, 48:40-46.
23. Delgado M.R., Nearing K.I., LeDoux J.E., Phelps E.A. Neural circuitry underlying the regulation of conditioned fear and its relation to extinction. Neuron 2008, 59:829-838.
24. Deschaux O., Zheng X., Lavigne J., Nachon O., Cleren C., Moreau J.-L., et al. Post-extinction fluoxetine treatment prevents stress-induced reemergence of extinguished fear. Psychopharmacology 2013, 225:209-216.
25. Difede J., Cukor J., Wyka K., Olden M., Hoffman H., Lee F.S., et al. D-cycloserine augmentation of exposure therapy for Post-Traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 2014, 39:1052-1058.
26. Dubicka B., Elvins R., Roberts C., Chick G., Wilkinson P., Goodyer I.M. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. British Journal of Psychiatry 2010, 197:433-440.
27. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
28. Ellard K.K., Fairholme C.P., Boisseau C.L., Farchione T.J., Barlow D.H. Unified protocol for the transdiagnostic treatment of emotional disorders: protocol development and initial outcome data. Cognitive and Behavioral Practice 2010, 17:88-101.
29. Farach F.J., Pruitt L.D., Jun J.J., Jerud A.B., Zoellner L.A., Roy-Byrne P.P. Pharmacological treatment of anxiety disorders: current treatments and future directions. Journal of Anxiety Disorders 2012, 26:833-843.
30. Goldapple K., Segal Z., Garson C., Lau M., Bieling P., Kennedy S., et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry 2004, 61:34-41.
31. Goldin P.R., Manber-Ball T., Werner K., Heimberg R., Gross J.J. Neural mechanisms of cognitive reappraisal of negative self-beliefs in social anxiety disorder. Biological Psychiatry 2009, 66:1091-1099.
32. Goossens L., Sunaert S., Peeters R., Griez E.J., Schruers K.R. Amygdala hyperfunction in phobic fear normalizes after exposure. Biological Psychiatry 2007, 62:1119-1125.
33. Gottfried J.A., Dolan R.J. Human orbitofrontal cortex mediates extinction learning while accessing conditioned representations of value. Nature Neuroscience 2004, 7:1144-1152.
34. Graham B.M., Langton J.M., Richardson R. Pharmacological enhancement of fear reduction: preclinical models. British Journal of Pharmacology 2011, 164:1230-1247.
35. Graham B.M., Milad M.R. The study of fear extinction: implications for anxiety disorders. American Journal of Psychiatry 2011, 168:1255-1265.
36. Hafner J., Milton F. The influence of propranolol on the exposure invivo of agoraphobics. Psychological Medicine 1977, 7:419-425.
37. Hart G., Harris J.A., Westbrook R.F. Systemic or intra-amygdala injection of a benzodiazepine (midazolam) impairs extinction but spares re-extinction of conditioned fear responses. Learning & Memory 2009, 16:53-61.
38. Hart G., Harris J.A., Westbrook R.F. Systemic or intra-amygdala infusion of the benzodiazepine, midazolam, impairs learning, but facilitates re-learning to inhibit fear responses in extinction. Learning & Memory 2010, 17:210-220.
39. Hart G., Panayi M.C., Harris J.A., Westbrook R.F. Benzodiazepine treatment can impair or spare extinction, depending on when it is given. Behaviour Research and Therapy 2014, 56:22-29.
40. Haug T.T., Blomhoff S., Hellstrøm K., Holme I., Humble M., Madsbu H.P., et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. British Journal of Psychiatry 2003, 182:312-318.
41. Hermann A., Schäfer A., Walter B., Stark R., Vaitl D., Schienle A. Emotion regulation in spider phobia: role of the medial prefrontal cortex. Social Cognitive and Affective Neuroscience 2009, 4:257-267.
42. Hefner K., Whittle N., Juhasz J., Norcross M., Karlsson R.R., Saksida L.M., et al. Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. The Journal of Neuroscience 2008, 28:8074-8085.
43. Hofmann S.G., Sawyer A.T., Korte K.J., Smits J.A.J. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? a meta-analytic review. International Journal of Cognitive Therapy 2009, 2:160-175.
44. Hofmann S.G., Wu J.Q., Boettcher H. D-cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biology of Mood & Anxiety Disorders 2013, 3:11.
45. Holmes A., Singewald N. Individual differences in recovery from traumatic fear. Trends in Neurosciences 2013, 36:23-31.
46. Jacobson N.S., Martell C.R., Dimidjian S. Behavioral activation treatment for depression: returning to contextual roots. Clinical Psychology: Science and Practice 2001, 8:255-270.
47. Julien R.M. Aprimer of drug action 2005, Worth Publishers, New York, NY. 10th ed.
48. Kalisch R., Korenfeld E., Stephan K.E., Weiskopf N., Seymour B., Dolan R.J. Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network. The Journal of Neuroscience 2006, 26:9503-9511.
49. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294:1030-1038.
50. Karpova N.N., Pickenhagen A., Lindholm J., Tiraboschi E., Kulesskaya N., Ágústsdóttir A., et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011, 334:1731-1734.
51. Kim M.J., Whalen P.J. The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety. The Journal of Neuroscience 2009, 29:11614-11618.
52. Langton J.M., Richardson R. The temporal specificity of the switch from NMDAr-dependent extinction to NMDAr-independent re-extinction. Behavioural Brain Research 2010, 208:646-649.
53. Langton J.M., Richardson R. The role of context in the re-extinction of learned fear. Neurobiology of Learning and Memory 2009, 92:496-503.
54. Langton J.M., Richardson R. D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33:3096-3102.
55. Lebrón-Milad K., Tsareva A., Ahmed N., Milad M.R. Sex differences and estrous cycle in female rats interact with the effects of fluoxetine treatment on fear extinction. Behavioural Brain Research 2013, 253:217-222.
56. Ledgerwood L., Richardson R., Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behavioral Neuroscience 2003, 117:341-349.
57. LeDoux J.E. Emotion circuits in the brain. Annual Review of Neuroscience 2000, 23:155-184.
58. Litz B.T., Salters-Pedneault K., Steenkamp M.M., Hermos J.A., Bryant R.A., Otto M.W., et al. Arandomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Research 2012, 46:1184-1190.
59. Lonsdorf T.B., Haaker J., Kalisch R. Long-term expression of human contextual fear and extinction memories involves amygdala, hippocampus and ventromedial prefrontal cortex: a reinstatement study in two independent samples. Social Cognitive and Affective Neuroscience 2014, 10.1093/scan/nsu018.
60. Marks I.M., Swinson R.P., Basoğlu M., Kuch K., Noshirvani H., O'Sullivan G., et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia a controlled study in London and Toronto. British Journal of Psychiatry 1993, 162:776-787.
61. McGaugh J. Memory - a century of consolidation. Science 2000, 287:248-251.
62. Michael T., Blechert J., Vriends N., Margraf J., Wilhelm F.H. Fear conditioning in panic disorder: enhanced resistance to extinction. Journal of Abnormal Psychology 2007, 116:612.
63. Milad M.R., Orr S.P., Lasko N.B., Chang Y., Rauch S.L., Pitman R.K. Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. Journal of Psychiatric Research 2008, 42:515-520.
64. Milad M.R., Pitman R.K., Ellis C.B., Gold A.L., Shin L.M., Lasko N.B., et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biological Psychiatry 2009, 66:1075-1082.
65. Milad M.R., Quinn B.T., Pitman R.K., Orr S.P., Fischl B., Rauch S.L. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:10706-10711.
66. Milad M.R., Quirk G.J. Fear extinction as a model for translational neuroscience: ten years of progress. Annual Review of Psychology 2012, 63:129-151.
67. Milad M.R., Quirk G.J., Pitman R.K., Orr S.P., Fischl B., Rauch S.L. Arole for the human dorsal anterior cingulate cortex in fear expression. Biological Psychiatry 2007, 62:1191-1194.
68. Milad M.R., Wright C.I., Orr S.P., Pitman R.K., Quirk G.J., Rauch S.L. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biological Psychiatry 2007, 62:446-454.
69. Mineka S., Zinbarg R. Acontemporary learning theory perspective on the etiology of anxiety disorders: it's not what you thought it was. American Psychologist 2006, 61:10-26.
70. Misanin J.R., Miller R.R., Lewis D.J. Retrograde amnesia produced by electroconvulsive shock after reactivation of a consolidated memory trace. Science 1968, 160:554-555.
71. Morin C.M., Colecchi C., Stone J., Sood R., Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. Journal of the American Medical Association 1999, 281:991-999.
72. Motzkin J.C., Philippi C.L., Wolf R.C., Baskaya M.K., Koenigs M. Ventromedial prefrontal cortex is critical for the regulation of amygdala activity in humans. Biological Psychiatry 2014, http://dx.doi.org/10.1016/j.biopsych.2014.02.014.
73. Mueller D., Cahill S.P. Noradrenergic modulation of extinction learning and exposure therapy. Behavioural Brain Research 2010, 208:1-11.
74. Mueller D., Porter J.T., Quirk G.J. Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. The Journal of Neuroscience 2008, 28:369-375.
75. Myers K.M., Davis M. Mechanisms of fear extinction. Molecular Psychiatry 2007, 12:120-150.
76. Nader K., Schafe G.E., LeDoux J.E. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000, 406:722-726.
77. Nave A.M., Tolin D.F., Stevens M.C. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. Journal of Clinical Psychiatry 2012, 73:1179-1186.
78. Norberg M.M., Krystal J.H., Tolin D.F. Ameta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63:1118-1126.
79. Otto M.W., Moshier S.J., Kinner D.G., Simon N.M., Pollack M.H., Orr S.P. De novo fear conditioning across diagnostic groups in the affective disorders: evidence for learning impairments. Behavior Therapy 2014, 45(24):619-629. http://dx.doi.org/10.1016/j.beth.2013.12.012.
80. Otto M.W., Pollack M.H., Sabatino S.A. Maintenance of remission following cognitive behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behavior Therapy 1996, 27:473-482.
81. Otto M.W., Smits J.A.J., Reese H.E. Cognitive-behavioral therapy for the treatment of anxiety disorders. Journal of Clinical Psychiatry 2004, 65(Suppl.5):34-41.
82. Orr S.P., Metzger L.J., Lasko N.B., Macklin M.L., Peri T., Pitman R.K. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. Journal of Abnormal Psychology 2000, 109:290.
83. Pereira M.E., Rosat R., Huang C.H., Godoy M.G.C., Izquierdo I. Inhibition by diazepam of the effect of additional training and of extinction on the retention of shuttle avoidance behavior in rats. Behavioral Neuroscience 1989, 103:202-205.
84. Peri T., Ben-Shakhar G., Orr S.P., Shalev A.Y. Psychophysiologic assessment of aversive conditioning in posttraumatic stress disorder. Biological Psychiatry 2000, 47:512-519.
85. Phelps E.A., Delgado M.R., Nearing K.I., LeDoux J.E. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 2004, 43:897-905.
86. Phelps E.A., LeDoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 2005, 48:175-187.
87. Quirk G.J., Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008, 33:56-72.
88. Rauch S.L., Whalen P.J., Shin L.M., McInerney S.C., Macklin M.L., Lasko N.B., et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biological Psychiatry 2000, 47:769-776.
89. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 2004, 61:1136-1144.
90. Rodebaugh T.L., Levinson C.A., Lenze E.J. Ahigh-throughput clinical assay for testing drug facilitation of exposure therapy. Depression and Anxiety 2013, 30:631-637.
91. Rodriguez-Romaguera J., Sotres-Bayon F., Mueller D., Quirk G.J. Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction. Biological Psychiatry 2009, 65:887-892.
92. Ritchey M., Dolcos F., Eddington K.M., Strauman T.J., Cabeza R. Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response. Journal of Psychiatric Research 2011, 45:577-587.
93. Rougemont-Bücking A., Linnman C., Zeffiro T.A., Zeidan M.A., Lebron-Milad K., Rodriguez-Romaguera J., et al. Altered processing of contextual information during fear extinction in PTSD: an fMRI study. CNS Neuroscience & Therapeutics 2011, 17:227-236.
94. Santini E., Muller R.U., Quirk G.J. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. The Journal of Neuroscience 2001, 21:9009-9017.
95. Schneier F.R., Neria Y., Pavlicova M., Hembree E., Suh E.J., Amsel L., et al. Combined prolonged exposure therapy and paroxetine for posttraumatic stress disorder related to the world trade center attacks: a randomized controlled trial. American Journal of Psychiatry 2012, 169:80-88.
96. Schienle A., Schäfer A., Hermann A., Rohrmann S., Vaitl D. Symptom provocation and reduction in patients suffering from spider phobia. European Archives of Psychiatry and Clinical Neuroscience 2007, 257:486-493.
97. Schienle A., Wabnegger A., Scharmüller W. Effects of cognitive behavior therapy on regional brain volume in spider-phobic patients: preliminary results. Journal of Anxiety Disorders 2014, http://dx.doi.org/10.1016/j.janxdis.2014.01.002.
98. Schwabe L., Nader K., Pruessner J.C. Reconsolidation of human memory: brain mechanisms and clinical relevance. Biological Psychiatry 2014, 76:274-280. http://dx.doi.org/10.1016/j.biopsych.2014.03.008.
99. Schwabe L., Nader K., Wolf O.T., Beaudry T., Pruessner J.C. Neural signature of reconsolidation impairments by propranolol in humans. Biological Psychiatry 2012, 71:380-386.
100. Sevenster D., Beckers T., Kindt M. Prediction error Governs pharmacologically induced amnesia for learned fear. Science 2013, 339:830-833.
101. Shin L.M., Orr S.P., Carson M.A., Rauch S.L., Macklin M.L., Lasko N.B., et al. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Archives of General Psychiatry 2004, 61:168-176.
102. Shin L.M., Wright C.I., Cannistraro P.A., Wedig M.M., McMullin K., Martis B., et al. Afunctional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Archives of General Psychiatry 2005, 62:273-281.
103. Simpson H.B., Liebowitz M.R., Foa E.B., Kozak M.J., Schmidt A.B., Rowan V., et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depression and Anxiety 2004, 19:225-233.
104. Smits J.A.J., Hofmann S.G., Rosenfield D., DeBoer D., Coster L.B., Simon P.T., et al. D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. Journal of Consulting and Clinical Psychology 2013, 81:1100-1112.
105. Smits J.A.J., Rosenfield D., Davis M.L., Julian K., Handelsman P.R., Otto M.W., et al. Yohimbine enhancement of exposure therapy for social anxiety" A randomized controlled trial. Biological Psychiatry 2014, 75:840-846.
106. Smits J.A.J., Rosenfield D., Otto M.W., Hofmann S.G., Telch M.J., Pollack M.H., et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biological Psychiatry 2013, 73:1054-1058.
107. Soeter M., Kindt M. Dissociation response systems: erasing fear from memory. Neurobiology of Learning and Memory 2010, 94:30-41.
108. Soeter M., Kindt M. Disrupting reconsolidation: pharmacological and behavioral manipulations. Learning & Memory 2011, 18:357-366.
109. Spiegel D.A., Bruce T.J., Gregg S.F., Nuzzarello A. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?. American Journal of Psychiatry 1994, 151:876-881.
110. Sripada R.K., Garfinkel S.N., Liberzon I. Avoidant symptoms in PTSD predict fear circuit activation during multimodal fear extinction. Frontiers in Human Neuroscience 2013, 7.
111. Straube T., Glauer M., Dilger S., Mentzel H.-J., Miltner W.H. Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage 2006, 29:125-135.
112. Straube T., Mentzel H.-J., Miltner W.H. Neural mechanisms of automatic and direct processing of phobogenic stimuli in specific phobia. Biological Psychiatry 2006, 59:162-170.
113. Sturm V., Lenartz D., Koulousakis A., Treuer H., Herholz K., Klein J.C., et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive-and anxiety-disorders. Journal of Chemical Neuroanatomy 2003, 26:293-299.
114. Tart C.D., Handelsman P.R., DeBoer L.B., Rosenfield D., Pollack M.H., Hofmann S.G., et al. Augmentation of exposure therapy with post-session administration of D-cycloserine. Journal of Psychiatric Research 2013, 41:168-174.
115. Todd T.P., Vurbic D., Bouton M.E. Behavioral and neurobiological mechanisms of extinction in Pavlovian and instrumental learning. Neurobiology of Learning and Memory 2014, 108:52-64.
116. Vidal-Gonzalez I., Vidal-Gonzalez B., Rauch S.L., Quirk G.J. Microstimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear. Learning & Memory 2006, 13:728-733.
117. Walker D.L., Ressler K.J., Lu K.-T., Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. The Journal of Neuroscience 2002, 22:2343-2351.
118. Weber M., Hart J., Richardson R. Effects of D-cycloserine on extinction of learned fear to an olfactory cue. Neurobiology of Learning and Memory 2007, 87:476-482.
119. Wells A., Clark D.M., Salkovskis P., Ludgate J., Hackmann A., Gelder M. Social phobia: the role of in-situation safety behaviors in maintaining anxiety and negative beliefs. Behavior Therapy 1995, 26:153-161.
120. Werner-Seidler A., Richardson R. Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine. Biological Psychiatry 2007, 62:1195-1197.
121. Westra H.A., Stewart S.H., Conrad B.E. Naturalistic manner of benzodiazepine use and cogintive behavioral therapy outcome in panic disorder with agoraphobia. Anxiety Disorders 2002, 16:233-246.
122. Whittle N., Schmuckermair C., Cinar O.G., Hauschild M., Ferraguti F., Holmes A., et al. Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology 2013, 64:414-423.
123. Yoshimura S., Okamoto Y., Onoda K., Matsunaga M., Okada G., Kunisato Y., et al. Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate cortex activity associated with self-referential processing. Social Cognitive and Affective Neuroscience 2013, 10.1093/scan/nst009.